Nephrol Dial Transplant (2000) 15: 451-452
© 2000 European Renal Association-European Dialysis and Transplant Association
Editorial Comments
STOPPING at the CAPPP of good HOPE
Franz Volhard Clinic at the Max Delbrück Center for Molecular Medicine, Medical Faculty of the Charité, Humboldt University of Berlin, Berlin, Germany
Correspondence and offprint requests to: Friedrich C. Luft, MD, Charité Campus-Buch, Franz Volhard Clinic, Wiltberg Str. 50, D-13125 Berlin, Germany.
Blood pressure lowering with medication has had a major effect on mortality and morbidity of cardiovascular disease. This achievement is one of the major medical highlights of the past 50 years. Inhibiting angiotensin converting enzyme (ACE) has proved a highly worthwhile clinical strategy that lowers blood pressure, but also has substantial effects on inhibiting the progression of heart failure, chronic renal disease, and perhaps the course of diabetes mellitus. Three recent clinical trials shed new information on ACE inhibitors in terms of blood pressure and cardiovascular risk reduction, as well as risk reduction in patients with cardiovascular risk factors in general. The information from these trials is important enough to warrant editorial comments.
The captopril prevention project (CAPPP)
References
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Glasspool Adherence: a major unmet need. CV Success Zone programme Eur. Heart J. Suppl., May 1, 2007; 9(suppl_B): B37 - B41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fournier, H. Mazouz, and J. M. Achard STOPPING at the CAPPP of good HOPE Nephrol. Dial. Transplant., January 1, 2001; 16(1): 185 - 187. [Full Text]
|
|